UNSPSC 51292014: Medifoxamine

This classification denotes a serotonin agonist and dopamine agonist with the molecular formula C16H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KWU7C2A1NT, chemically known as n,n-dimethyl-2,2-diphenoxyethylamine but generally known as medifoxamine, which bears US NIH Compound Identifier 36109. European Medicines Agency schedules Medifoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08693MIG. The term MEDIFOXAMINE is an International Non-Proprietary Name.

UNSPSC 51292014 Medifoxamine is a Commodity code that does not match the work actually being solicited under it in recent state and local opportunities. The code's nominal scope — a specific pharmaceutical compound — bears no relation to the three recent opportunities tagged with this code, which solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products. The mismatch suggests either a classification error in the source data or a practice of using a single pharmaceutical code as a catch-all for diverse pharmacy procurement. State and local issuers using this code include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). The opportunities themselves span product procurement, market intelligence gathering, and contract establishment across multiple jurisdictions and vendor networks.

Recent activity shows three distinct procurement approaches across the Southeast and Upper Midwest. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, requiring quarterly deliveries to a community health building with fixed-fee pricing and a two-year initial term plus one-year renewal option. Texas HHS issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program without a formal competitive timeline or award value, seeking vendor experience with direct contracting and negotiated net pricing outside traditional pharmacy benefit manager arrangements. MMCAP released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with a March 26, 2026 response deadline, evaluation weighted 75 percent on price competitiveness, and contract effectiveness July 1, 2026. The code shows limited decision-relevant recent activity; the pharmaceutical-procurement classification does not usefully predict which issuing bodies or geographies will post under it next.